Affitech A/S strengthens its IP portfolio on anti-VEGF antibody AT001/r84

14-Oct-2011 - Norway

Affitech A/S announced that the U.S. Patent and Trademark Office (USPTO) has granted Affitech U.S. patent (no. 8,034,905) covering the Company’s anti-VEGF antibody drug candidate AT001/r84. The newly granted US patent is the first patent grant Affitech has received for this compound in a major territory and it considerably strengthens Affitech's IP position regarding this drug candidate. The patent is co-owned by Affitech and its collaboration partner Peregrine Pharmaceuticals.

Commenting on the new patent, Managing Director of Affitech A/S Martin Welschof said: “The grant of the patent on AT001/r84 by the USPTO is pleasant news. We hereby extend our patent portfolio for AT001/r84 to include USA, which is important for the further development of this antibody drug candidate. The development of AT001/r84 is progressing well and IBC Generium expects to commence the first phase 1 clinical trial with the drug candidate before year end 2011.”

AT001/r84 is a proprietary therapeutic antibody to vascular endothelial growth factor (VEGF) being developed by Affitech and IBC Generium as a potential alternative to bevacizumab (Avastin®) for the treatment of certain human cancers. The Russian health authorities have identified cancer therapy based on anti-VEGF antibodies as one of the top priority areas of pharma-innovation in Russia. Affitech’s AT001/r84 has the potential to satisfy patient needs in this area. The rights to develop and commercialize AT001/r84 outside Russia and the CIS remain with Affitech. 

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous